Disease · MONDO_0007896

acute monocytic leukemia

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. acute monocytic leukemia. Diseases, record MONDO_0007896. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0007896

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: acute monocytic leukemia; Open Targets
Open Targets ID: MONDO_0007896; Open Targets
Other names: AML M5, AMoL, Acute monoblastic leukaemia, Acute monoblastic leukemia, Acute monocytic leukaemia, acute monoblastic leukaemia and acute monocytic leukaemia, acute monoblastic leukemia and acute monocytic leukemia, acute monocytic leukaemia (FAB M5B), acute monocytic leukemia (FAB M5B), acute monocytic leukemia without mention of remission, acute monocytic leukemia, FAB M5, acute monocytic leukemia, morphology, acute monocytic leukemia, morphology (morphologic abnormality), leukemia, monocytic, malignant, monocytic leukemia, monocytic leukemia, acute; Open Targets
Disease Ontology: DOID:8864; Disease Ontology
MeSH: D007948; MeSH
NCI Thesaurus: C4861; NCI Thesaurus
Orphanet: ORPHA:514; Orphanet
Highest stage of its drugs: Phase 2/3, for 5 of its 24 drugs, from ClinicalTrials.gov; Open Targets

Drugs24

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
CYTARABINE	CHEMBL803	Small molecule	Phase 2/3	ClinicalTrials.gov	4	4	4	Drugs and targets
CLADRIBINE	CHEMBL1619	Small molecule	Phase 2/3	ClinicalTrials.gov	1	1	1	Drugs and targets
IDARUBICIN	CHEMBL1117	Small molecule	Phase 2/3	ClinicalTrials.gov	1	1	1	Drugs and targets
MITOXANTRONE	CHEMBL58	Small molecule	Phase 2/3	ClinicalTrials.gov	1	1	1	Drugs and targets
SORAFENIB	CHEMBL1336	Small molecule	Phase 2/3	ClinicalTrials.gov	1	1	1	Drugs and targets
AZACITIDINE	CHEMBL1489	Small molecule	Phase 2	ClinicalTrials.gov	5	5	5	Drugs and targets
VENETOCLAX	CHEMBL3137309	Small molecule	Phase 2	ClinicalTrials.gov	5	5	5	Drugs and targets
DECITABINE	CHEMBL1201129	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
TUCIDINOSTAT	CHEMBL3621988	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
ACLARUBICIN	CHEMBL502620	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets

1 to 10 of 24

See all 24 drugs

Targets40

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
TOP2A	DNA topoisomerase 2-alpha	4	DNA topoisomerase II alpha inhibitor; DNA topoisomerase II inhibitor	Phase 2/3	https://conductscience.org/library/genes/7153	Drugs and targets
CRBN	CRL4(CRBN) E3 ubiquitin ligase	2	CRL4(CRBN) E3 ubiquitin ligase inhibitor; CRL4(CRBN) E3 ubiquitin ligase modulator	Phase 2	https://conductscience.org/library/genes/51185	Drugs and targets
CUL4A	CRL4(CRBN) E3 ubiquitin ligase	2	CRL4(CRBN) E3 ubiquitin ligase inhibitor; CRL4(CRBN) E3 ubiquitin ligase modulator	Phase 2	https://conductscience.org/library/genes/8451	Drugs and targets
DDB1	CRL4(CRBN) E3 ubiquitin ligase	2	CRL4(CRBN) E3 ubiquitin ligase inhibitor; CRL4(CRBN) E3 ubiquitin ligase modulator	Phase 2	https://conductscience.org/library/genes/1642	Drugs and targets
DNMT1	DNA (cytosine-5)-methyltransferase 1	2	DNA (cytosine-5)-methyltransferase 1 inhibitor	Phase 2	https://conductscience.org/library/genes/1786	Drugs and targets
DNMT3A	DNA (cytosine-5)-methyltransferase 3A	2	DNA (cytosine-5)-methyltransferase 3A inhibitor	Phase 2	https://conductscience.org/library/genes/1788	Drugs and targets
POLA1	DNA polymerase (alpha/delta/epsilon)	2	DNA polymerase (alpha/delta/epsilon) inhibitor	Phase 2/3	https://conductscience.org/library/genes/5422	Drugs and targets
POLA2	DNA polymerase (alpha/delta/epsilon)	2	DNA polymerase (alpha/delta/epsilon) inhibitor	Phase 2/3	https://conductscience.org/library/genes/23649	Drugs and targets
POLD1	DNA polymerase (alpha/delta/epsilon)	2	DNA polymerase (alpha/delta/epsilon) inhibitor	Phase 2/3	https://conductscience.org/library/genes/5424	Drugs and targets
POLD2	DNA polymerase (alpha/delta/epsilon)	2	DNA polymerase (alpha/delta/epsilon) inhibitor	Phase 2/3	https://conductscience.org/library/genes/5425	Drugs and targets

1 to 10 of 40

See all 40 targets

Trials9

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT01522976	Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia	Phase 2	282	2016-03-22	Chronic Myelomonocytic Leukemia, Chronic Myelomonocytic Leukemia-1, Chronic Myelomonocytic Leukemia-2, Myelodysplastic Syndrome, Myelodysplastic Syndrome With Excess Blasts, Myelodysplastic Syndrome With Excess Blasts-1, Myelodysplastic Syndrome/Acute Myeloid Leukemia	AZACITIDINE, LENALIDOMIDE, VORINOSTAT	Open Targets' reading of its record	ClinicalTrials.gov
NCT04802161	Comparing the Addition of an Anti-Cancer Drug, Pomalidomide, to the Usual Chemotherapy Treatment (Daunorubicin and Cytarabine Liposome) in Newly Diagnosed Acute Myeloid Leukemia With Myelodysplastic Syndrome-Related Changes	Phase 2	49	2025-12-19	Acute Myeloid Leukemia, Acute Myeloid Leukemia Post Cytotoxic Therapy, Acute Myeloid Leukemia With Multilineage Dysplasia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Myeloproliferative Neoplasm	CYTARABINE, DAUNORUBICIN, POMALIDOMIDE	Open Targets' reading of its record	ClinicalTrials.gov
NCT03404193	Venetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed High-Risk Myelodysplastic Syndrome	Phase 2	235		Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Blastic Plasmacytoid Dendritic Cell Neoplasm, Chronic Myelomonocytic Leukemia, Mixed Phenotype Acute Leukemia, Myelodysplastic Syndrome, Recurrent Acute Biphenotypic Leukemia, Recurrent Acute Myeloid Leukemia, Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm, Recurrent Chronic Myelomonocytic Leukemia, Recurrent Mixed Phenotype Acute Leukemia, Refractory Acute Myeloid Leukemia, Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm, Refractory Chronic Myelomonocytic Leukemia, Refractory Mixed Phenotype Acute Leukemia	DECITABINE, VENETOCLAX	Open Targets' reading of its record	ClinicalTrials.gov
NCT07512700	Venetoclax Combined With CACAG Regimen Versus "3+7" Regimen in the Treatment of Acute Monocytic Leukemia	Phase 2	204		Acute Monocytic Leukemia	ACLARUBICIN, AZACITIDINE, CYTARABINE, TUCIDINOSTAT, VENETOCLAX	Its record names the disease	ClinicalTrials.gov
NCT05566054	Venetoclax and Azacitidine Combined With Chidamide (VAC) for the Treatment of Newly Diagnosed Acute Monocytic Leukemia	Phase 2	92		Acute Monocytic Leukemia, Newly Diagnosed	AZACITIDINE, TUCIDINOSTAT, VENETOCLAX	Its record names the disease	ClinicalTrials.gov
NCT03418038	Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia	Phase 2	80		Clonal Cytopenia of Undetermined Significance, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Hodgkin Lymphoma, Recurrent Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Lymphoma, Chronic Myelomonocytic Leukemia	ASCORBIC ACID, CARBOPLATIN, CISPLATIN, CYTARABINE, DECITABINE, DEXAMETHASONE, ETOPOSIDE, GEMCITABINE HYDROCHLORIDE, IFOSFAMIDE, OXALIPLATIN, RITUXIMAB	Open Targets' reading of its record	ClinicalTrials.gov
NCT04160052	Venetoclax and Azacitidine for the Treatment of High-Risk Recurrent or Refractory Myelodysplastic Syndrome	Phase 1/2	51		Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Recurrent Myelodysplastic Syndrome, Refractory Myelodysplastic Syndrome, Therapy-Related Myelodysplastic Syndrome	AZACITIDINE, VENETOCLAX	Open Targets' reading of its record	ClinicalTrials.gov
NCT05313958	Treateament of Newly Diagnosed Acute Monocytic Leukemia in Children	Phase 2/3	43		Leukemia, Monocytic, Acute, Pediatric AML	CLADRIBINE, CYTARABINE, IDARUBICIN, MITOXANTRONE, SORAFENIB	Its record names the disease	ClinicalTrials.gov
NCT03862157	Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia	Phase 1/2	40		Acute Myeloid Leukemia, Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, Chronic Eosinophilic Leukemia, Not Otherwise Specified, Chronic Myelomonocytic Leukemia, Chronic Neutrophilic Leukemia, Essential Thrombocythemia, Myelodysplastic Syndrome, Myelodysplastic/Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Myeloid Neoplasm, Myeloproliferative Neoplasm, Myeloproliferative Neoplasm, Unclassifiable, Overt Primary Myelofibrosis, Polycythemia Vera, Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase, Prefibrotic/Early Primary Myelofibrosis	AZACITIDINE, PEVONEDISTAT, VENETOCLAX	Open Targets' reading of its record	ClinicalTrials.gov

Comparisons in its trials0

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

None in this release.

Papers from its trials12

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
31279288	RESULT	1	PubMed
19242495	RESULT	1	PubMed
39352751	DERIVED	1	PubMed
37422688	DERIVED	1	PubMed
36063832	DERIVED	1	PubMed
34474640	DERIVED	1	PubMed
34255353	DERIVED	1	PubMed
33792630	DERIVED	1	PubMed
33580980	DERIVED	1	PubMed
33027528	DERIVED	1	PubMed

1 to 10 of 12

See all 12 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0007896

GET https://conductscience.org/api/diseases/v1/MONDO_0007896/drugs?page=2

API reference For AI assistants